Original articleIxekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
Section snippets
Study design and treatments
In this 52-week, phase 3b, double-blind, head-to-head trial (IXORA-S [NCT02561806]), eligible patients16 with moderate-to-severe plaque psoriasis were randomized 1:1 to receive subcutaneous injections of either ixekizumab or ustekinumab per the recommended dosing regimen (Fig 1).17, 18 Matching placebo injections were used to maintain blinding. The study methods were previously described in depth.16
Study population
Eligibility and exclusion criteria have been reported previously.16 Of note, eligible study
Study population
Of the 355 patients screened for IXORA-S (Fig 2), 302 were randomized to receive ustekinumab (n = 166) or ixekizumab (n = 136). The numbers of patients in both treatment groups who discontinued during the maintenance period were comparable, with 91% of patients completing the study through week 52 (151 of those who received ustekinumab [91.0%] and 124 of those who received ixekizumab [91.2%]). The most common reasons for discontinuation during the maintenance period were subject decision (8
Discussion
This 1-year analysis of the IXORA-S study shows that the superiority of ixekizumab over ustekinumab in patients with moderate-to-severe psoriasis was maintained through week 52. A PASI 90 response was sustained through 1 year by 76.5% of the ixekizumab-treated patients, and 52.2% had completely clear skin at week 52 (NRI analysis). When the NNT was considered, the superiority of treatment with ixekizumab over treatment with ustekinumab translated into 1 additional patient reaching PASI 90 for
References (25)
- et al.
The IL-23/Th17 axis in the immunopathogenesis of psoriasis
J Invest Dermatol
(2009) - et al.
Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation
Immunity
(2011) - et al.
Dermal γδ T cells—a new player in the pathogenesis of psoriasis
Int Immunopharmacol
(2013) - et al.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Lancet
(2015) - et al.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
J Am Acad Dermatol
(2015) - et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Lancet
(2008) - et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Lancet
(2008) - et al.
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
Lancet
(2005) - et al.
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study
J Am Acad Dermatol
(2006) - et al.
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
J Am Acad Dermatol
(2014)
Immunology of psoriasis
Annu Rev Immunol
The role of IL-23 in the immunopathogenesis of psoriasis
F1000 Biol Rep
Cited by (0)
Funding sources: Supported in full by Eli Lilly and Company, Indianapolis, Indiana. Dr Griffiths is a National Institute for Health Research senior investigator.
Disclosure: Dr Paul has served as consultant and/or investigator for AbbVie, Amgen, Boehringer, Celgene, Eli Lilly and Company, Janssen, Leo, Novartis, and Pfizer. Dr Griffiths reports grants and personal fees from Eli Lilly and Company during the conduct of the study and grants and personal fees from AbbVie, Janssen, Celgene, Novartis, Pfizer, and GSK-Stiefel; grants from Sandoz, LEO Pharma, MMS, MSD, Sanofi, and Roche; personal fees from Amgen, UCB Pharma, Sun Pharmaceuticals, and MedScape; and, stock/stock options from CG Skin outside the submitted work. Dr van de Kerkhof has served as a consultant for Celgene, Centocor, Allmirall, Amgen, Pfizer, Philips, Abbott, Eli Lilly and Company, Galderma, Novartis, Jansen Cilag, Leo Pharma, Sandoz, and Mitsibishu and has worked as an investigator for Basilea, Pfizer, Eli Lilly and Company, Amgen, Abbvie, Philips Lighting, Jansen Cilag, and Leo Pharma. Dr Puig has been a clinical trial investigator for AbbVie, Amgen, GSK, Janssen, Eli Lilly and Company, MSD, Novartis, Pfizer, Regeneron, and VBL; he has also been a paid adviser/speaker for AbbVie, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, GSK, Janssen, Leo-Pharma, Eli Lilly and Company, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Sandoz, Sanofi, and VBL. Dr Dutronc, Dr Henneges, Dr Dossenbach, and Dr Hollister are employees of Eli Lilly and Company and receive a salary from and own stock in the company. Dr Reich has served as adviser and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Leo, Eli Lilly and Company, Medac, Merck Sharp & Dohme Corp, Novartis, Pfizer, Regeneron, Takeda, UCB Pharma, and Xenoport.
Although the primary objective of this paper is to disclose efficacy and safety for IXORA-S at week 52, data for weeks 0 to 24 are provided for context. The data for weeks 0 to 24 data were previously published in the following article: Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177:1014-1023.
Reprints not available from the authors.